Mersana Therapeutics Inc (MRSN) concluded trading on Thursday at a closing price of $0.61, with 3.58 million shares of worth about $2.18 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -54.87% during that period and on February 13, 2025 the price saw a loss of about -5.58%. Currently the company’s common shares owned by public are about 122.87M shares, out of which, 86.40M shares are available for trading.
Stock saw a price change of -10.89% in past 5 days and over the past one month there was a price change of -3.90%. Year-to-date (YTD), MRSN shares are showing a performance of -57.39% which decreased to -84.50% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.49 but also hit the highest price of $6.28 during that period. The average intraday trading volume for Mersana Therapeutics Inc shares is 4.62 million. The stock is currently trading -2.51% below its 20-day simple moving average (SMA20), while that difference is down -52.35% for SMA50 and it goes to -67.56% lower than SMA200.
Mersana Therapeutics Inc (NASDAQ: MRSN) currently have 122.87M outstanding shares and institutions hold larger chunk of about 59.20% of that.
The stock has a current market capitalization of $75.27M and its 3Y-monthly beta is at 1.63. It has posted earnings per share of -$0.61 in the same period. It has Quick Ratio of 2.35 while making debt-to-equity ratio of 30.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for MRSN, volatility over the week remained 9.57% while standing at 14.15% over the month.
Stock’s fiscal year EPS is expected to rise by 58.87% while it is estimated to decrease by -12.89% in next year. EPS is likely to grow at an annualized rate of 20.92% for next 5-years, compared to annual growth of 11.93% made by the stock over the past 5-years.
Coverage by Citigroup stated Mersana Therapeutics Inc (MRSN) stock as a Buy in their note to investors on November 15, 2024, suggesting a price target of $5 for the stock. On March 19, 2024, JP Morgan Upgrade their recommendations, while on February 29, 2024, Wedbush Upgrade their ratings for the stock with a price target of $7. Stock get a Buy rating from Guggenheim on February 29, 2024.
